Introduction {#s0001}
============

In 1988, the World Health Organization defined thyroid cancer (TC) with a maximum tumor diameter of 10 mm as micro-carcinoma. Up to now, doctors in different countries and regions of the world still differ significantly on how to treat such diseases, including on whether to perform preventive lymph node dissection in the central region of the cancer. As the AJCC raised the age factor in the clinical staging of TC from 45 to 55 in 2017, it can be seen that the medical community tends to be more conservative in general on surgical treatment of TC. Based on clinical staging of TC in the AJCC Cancer Staging Manual, 8th edition, this study aimed to explore the characteristics of CLNM of PTMC in the elderly population (≥55 years) so as to provide some references for developing clinical treatment plans for such patients.

Methods {#s0002}
=======

Patients {#s0002-s2001}
--------

We retrospectively analyzed the data of patients with PTMC admitted to the Head and Neck Surgery Center of Sichuan Cancer Hospital, Chengdu, China, from January 2015 to September 2018. Eligible patients were screened in strict accordance with our inclusion and exclusion criteria for relevant data statistics and analysis. Inclusion criteria were as follows: 1) Patient age was ≥55 years. 2) All of the patients had been newly diagnosed and newly treated, with no previous history of thyroid surgery. 3) Postoperative pathological diagnosis based on paraffin-embedded sections was papillary carcinoma. 4) Benign nodules with or without pathology and \>10 mm in maximum diameter suggested by preoperative color ultrasound. 5) Patients' complete medical records were available. 6) All of the surgeons had \>10 years' experience in thyroid surgery. 7) Patients had undergone surgical resection of glandular lobes and isthmus on the affected side, as well as lymph node dissection in the central region with or without lateral cervical lymph node dissection. Exclusion criteria were as follows: 1) Postoperative pathology indicated mixed carcinoma with papillary and other types of carcinoma. 2) Patient had refused lymph node dissection in the central area on the affected side. 3) There were multiple cancer lesions, with the sum of the maximum diameter \>10 mm.

Surgical Technique {#s0002-s2002}
------------------

All of the patients had been operated on according to the "at least 2" principle, namely lymph node dissection at least in the central area on the cancerous side. Total thyroidectomy, bilateral central-area lymph node dissection with or without lateral cervical lymph node dissection were performed on patients with preoperative cytological confirmation of bilateral multi-lobed carcinoma or lateral cervical lymph node metastasis. Those with papillary micro-carcinoma in one glandular lobe and benign nodules in the other glandular lobe (i.e., multiple nodules) with maximum diameter of \>10 mm underwent concurrent total thyroidectomy and bilateral central lymph node dissection. Central-region lymph nodes were dissected in the following areas: upper boundary--lower hyoid margin, lower boundary--superior sternal fossa (upper margin of the unknown artery), and external--lateral margin of the carotid sheath and lower boundary--anterior vertebral fascia.

Statistical Analysis {#s0002-s2003}
--------------------

We used SPSS software version 25.0 (SSPS, Inc., Chicago, Illinois, US) to statistically analyze all of the data. In our analysis of risk factors for lymph node metastasis in the central region, we performed single-factor analysis using *χ*^2^ test. We ran multivariate logistic-regression analysis on statistically significant positive univariate influencing factors, as well as univariate and multivariate receiver operating curve (ROC) analysis on the previously analyzed risk factors to predict lymph node metastasis in the central region.

Results {#s0003}
=======

We screened a total of 712 PTMC cases. Of these, 107 met the inclusion criteria, including 24 men and 83 women, with a male-to-female ratio of 1:3.46. Patients' age range was 55--74 years old, with a median of 59.99 ± 4.58 years. The maximum diameter range of the cancer lesion was 4--10 mm, median 7.59 ± 1.78 mm. There were 77 cases (71.96%) with single-leaf single-focus, 9 (8.41%) with single-leaf multi-focus and 21 (19.63%) with multi-leaf multi-focus. Unilateral lobectomy was performed in 32 cases and total thyroidectomy in 75 cases and lateral cervical lymph node dissection in 21 cases. In terms of staging, 70.10% of cases were in stage T1 (75/107), 22.42% in stage T3 (24/107), and 7.48% in stage T4 (8/107). Postoperative pathology showed CLNM in 60 cases (56.07%) and lateral cervical lymph node metastasis in 13 cases (12.10%).

Evaluation of Central Lymph Nodes by Color Doppler Ultrasound {#s0003-s2001}
-------------------------------------------------------------

Preoperative ultrasound examination indicated 7 stage cN1a cases and 100 stage cN0 cases. Postoperative pathology confirmed 60 stage pN1a cases and 47 stage pN0 cases, which were significantly different. Predictive sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 1.00, 47.00%, 11.67%, and 1.00%, respectively ([Table 1](#t0001){ref-type="table"}).Table 1Comparison of Preoperative Ultrasound Predictions of Central-Region Lymph Node MetastasisNUltrasonic StagingTotalSensitivity = 1.00cN1acN0Specificity = 47.00%Pathological stagepN1a75360PPV = 11.67%pN004747NPV = 1.00Total7100107Matching rate = 50.47%[^1]

Univariate Analysis {#s0003-s2002}
-------------------

In this study, single-factor analysis of 107 patients with PTMC age ≥55 years showed that distribution, nodule morphology, calcification and extra-thyroidal expansion of cancer focus significantly influenced central-region lymph node metastasis (*P* \< 0.05). However, patients' gender, thyroid-stimulating hormone (TSH) levels, thyroglobulin (Tg) levels, nodular goiter, Hashimoto's thyroiditis, maximum diameter of cancer focus, nodular boundary, and nodular blood flow had no statistical significance on such metastasis ([Table 2](#t0002){ref-type="table"}).Table 2Single-Factor Analysis of Central-Region Lymph Node MetastasisFactorsNumber (n=107)Central Lymph Node Metastasis (CLNM)*χ*^2^*P*Yes (n = 47)No (n = 60)**Gender**2.7360.098 Male24717 Female834043**TSH levels**0.1450.704 Normal863749 Abnormal211011**Tg levels**--1.000 Normal994455 Abnormal835**Nodular goiter**1.2260.268 Yes552728 No522032**Hashimoto's thyroiditis**0.1020.749 Yes22913 No853847**Distribution of carcinoma**9.9920.005 Unilateral glandular lobes, single foci774136 Unilateral glandular lobes, multiple foci918 Bilateral glandular lobes, multiple foci21516**Maximum diameter**2.8380.092 ≤5 mm1284 5 mm \< x ≤ 10 mm953956**Boundary**--0.329 Clear1064 Unclear974156**Echo**--0.581 Low or no1044559 Strong or mixed321**Extra-thyroidal expansion**21.353\<0.01 Yes631647 No443113**Calcification**5.5410.019 Yes702545 No372215**Blood flow**0.4390.508 Rich632637 Not rich442123[^2]

Multivariate Logistic-Regression Analysis {#s0003-s2003}
-----------------------------------------

Factors that had been statistically significant in univariate-analysis results were further included in multivariate logistic-regression analysis; variables that might be clinically relevant but had been negative in univariate analysis were also included. We found that distribution, morphology and extra-thyroidal expansion of cancer focus were independent risk factors for CLNM (*P* \< 0.05), while gender, TSH, Tg, nodular goiters, Hashimoto's thyroiditis, nodular boundary, blood flow, calcification, and maximum diameter had no predictive significance ([Table 3](#t0003){ref-type="table"}).Table 3Multivariate Logistic-Regression Analysis of Lymph Node Metastasis in the Central RegionFactorsβSEWald*P*OR95% CI ORGender0.9580.6712.0360.1542.6060.699--9.714Distribution of carcinoma0.9680.3587.3010.0072.6321.304--5.310Maximum diameter−0.1090.1600.4610.4970.8970.656--1.227Tumor formation pattern3.2261.1218.2820.00425.1722.798--226.477Boundary−1.7521.2182.0700.1500.1730.016--1.886Extra-thyroidal expansion2.1120.53515.5680.0008.2672.895--23.606Calcification1.0820.5813.4680.0632.9500.945--9.209Blood flow0.2300.5330.1860.6661.2580.443--3.577[^3]

ROC Curve Analysis {#s0003-s2004}
------------------

We performed ROC curve analysis according to the independent risk factors obtained in our multivariate logistic regression analysis of CLNM, as discussed above, and we calculated areas under the curve (AUCs; [Figures 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}).Figure 1Areas under the curve (AUC). Distribution of carcinoma, AUC = 0.632; extra-thyroidal expansion, AUC = 0.721; tumor formation pattern, AUC = 0.603.Figure 2Multiple independent risk factors predicted lymph node metastasis in the central region. Areas under the curve (AUC)= 0.803.

Discussion {#s0004}
==========

Disease Status of TC {#s0004-s2001}
--------------------

The incidence of TC has been on the rise globally over the past 30 years, which has been confirmed by most current studies.[@cit0001]--[@cit0003] According to International Agency for Research on Cancer (IARC) data for 2018, a total of 567,233 new cases (male:female = 1:3.33) and 41,071 deaths (male:female = 1:1.64) were reported in 185 countries around the world, respectively, accounting for 3.1% and 0.4% of all new cancer cases and deaths.[@cit0004] On the one hand, due to the great influence of medical ultrasound and cytological-puncture diagnosis, the proportion of PTMC in new cases of TC has increased significantly. According to the data, the overall incidence of PTMC in the United States has increased by 441% over the past 30 years, with average annual new cases accounting for about 49%.[@cit0005]--[@cit0009] On the other hand, PTMC incidence in the elderly is significantly higher than that in the general adult population. Some studies have shown that the average annual growth rate of PTMC in patients \>65 years old is 1.4 times that in adults \<65 years old.[@cit0008]--[@cit0010] These results indicate that we should pay sufficient attention to elderly PTMC patients. As the 8th edition of the AJCC Cancer Staging Manual raise PTC staging age from 45 to 55 years old, it further confirms this view.

Therapeutic Controversies {#s0004-s2002}
-------------------------

As we all know, diagnosis and treatment of PTMC have always been controversial, especially in elderly patients. In Japan's Kuma hospital, Ito et al defined the maximum diameter of thyroid cancer foci ≤1.0cm, no cervical, and distant lymph node metastasis, and cytological biopsy of thyroid cancer foci as non-highly malignant and no invasion of the trachea and recurrent laryngeal nerve as the judgment criteria for low-risk PTMC. After analyzing the data of 4023 patients, they concluded that immediate surgical treatment of all PTMC patients was more harmful than beneficial, so they suggested that low-risk PTMC patients should choose active observation. Among them, elderly PTMC patients over 60 years old were considered to be the most suitable group for observation.[@cit0011],[@cit0012] Conversely, Megwalu UC of the National Cancer Center (Plainview, New York, US) reviewed 2323 cases in which senile PTMC patients age ≥65 received non-operative therapy. His data analysis shows that the overall 5-year survival rate was 23% and the surgery was 91% (*P* \< 0.0001), which suggests that surgery for such patients has a survival advantage, although more high-quality investigative studies are necessary.[@cit0001] "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer" suggested that suspicious malignant thyroid nodules with a maximum diameter of \<1.00 cm be followed up to 1.00 cm for cytological puncture and other treatments, but immediate surgical treatment is still recommended for high-risk patients. In this study, we performed surgical treatment on all PTMC patients with clear diagnoses, including stage T1 (70.10%, 75/107), T3 (22.42%, 24/107) and T4 (7.48%, 8/107). Although the study sample size needs to be further expanded, we still believe that micro-carcinoma is not equal to early cancer. The percentage of differentiated tumor cells in elderly PTC patients is relatively higher than in youth and children, leading to shorter life expectancy. Choosing follow-up for middle-aged and elderly PTMC patients may be feasible, but for those with longer life expectancy, early surgery can significantly reduce future progress of tumors may not only, but also reduced the forward of surgery as a result of basic diseases such as cardiovascular increase intolerance. Therefore, for PTMC patients age ≥55 with good survival expectations, we believe surgical intervention is still necessary, which is also consistent with Shindo et al.[@cit0013]

Risk Factors {#s0004-s2003}
------------

In the past, there have been many studies analyzing PTMC-CLNM, but few such reports address elderly patients with PTMC. Due to air interference in the tracheal cavity, it is relatively difficult to diagnose CLNM of the neck using ultrasound, which has a high false-negative rate. In this study, the accuracy of ultrasound in predicting CLNM was 50.47%. Therefore, it is questionable whether dissection of such lymph nodes can be performed only by preoperative ultrasound. Chung et al[@cit0014] found that in young PTMC patients, multiple cancer foci, enlarged nodules, extra-thyroidal expansion of cancer focus, and vascular invasion are independent risk factors for PTMC-CLNM and lateral cervical lymph node metastasis, but they did not clearly identify calcified nodules as an independent risk factor. By analyzing the data of 379 PTMC patients, Oh et al[@cit0015] showed that the rate of lymph node metastasis in patients with calcified nodules was 17.8% higher than in patients whose nodules were not calcified; they concluded that calcified nodules were an important risk factor for PTMC cervical lymph node metastasis. Haugen et al[@cit0016] have a similar view. In this study, the metastasis rates of the central cervical region and lateral cervical lymph nodes were 56.07% (60/107) and 12.10% (13/107), respectively. The *χ*^2^ test showed that distribution, nodular morphology, calcification and extra-thyroidal expansion of cancer focus were risk factors for central-region lymph nodes (*P* \< 0.05), which was consistent with Liu et al.[@cit0017] However, our multivariate logistic-regression analysis found that only distribution of cancer lesions (*χ*^2^= 7.301; *P* = 0.007), nodule morphology (*χ*^2^ = 8.282; *P* = 0.004), and extra-thyroidal expansion of cancer focus (*χ*^2^ = 15.568; *P* \< 0.001) were independent risk factors for such metastasis. The AUCs of these 3 factors were 0.632, 0.603 and 0.721, respectively, and overall predictability was 80.30%.

In summary, we believe that active follow-up and observation should be carefully selected for elderly patients with PTMC, especially for those with multiple cancer foci, extra-thyroidal expansion of cancer focus, and irregular morphology; preventive central-area lymph node dissection is also appropriate. Although we did not find nodular calcification, maximum tumor diameter, Hashimoto's thyroiditis, or other variables to be independent risk factors, we believe this result may have a certain relationship with the small sample size, which we will further expand in the future for related studies and supplements.
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[^1]: **Abbreviations:** PPV, positive predictive value; NPV, negative predictive value.

[^2]: **Abbreviations:** TSH, thyroid-stimulating hormone; Tg, thyroglobulin.

[^3]: **Abbreviations:** SE, Standard error; OR, odds ratio; CI, confidence interval.
